Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease

Bosman, Alexis; Edel, Michael J.; Blue, Gillian M.; Dilley, Rodney J.; Harvey, Richard P.; Winlaw, David S.

doi:10.3390/jcm4040768

Cited by 8 publications

(11 citation statements)

References 77 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These c-kit+CD45-(deletion of which also renders the cells CD31-, CD34-) CPCs were also shown to express to some degree Sca-1, Abcg2, CD105, CD166, PDGFR-α, Flk-1, ROR2, CD13, and CD90 [172]. The number of CPCs have however been shown to be significantly higher in neonates but dramatically decreases after the age of 2 [71,173]. Thus, these CPCs in combination with a suitable scaffold, could be the answer to treat a number of CHD, as CPCs could be collected during palliative surgery or via endomyocardial biopsy [19,64].…”

Section: Cardiac Progenitor Cellsmentioning

confidence: 99%

“…Lu et al have further examined the effects of pharmacological agents on repopulated heart and observed remarkable responses [141]. This model is explored as an option to personalized medicine concerning drug testing/discovery [141,152]. Specifically, for CHD which presents such a variety of profiles, individual patient-specific human models' development could help to understand how each patient would respond to existing pharmaceutical treatments.…”

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Peer Review #1 of "Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease (v0.2)"

Ellison-Hughes¹

2018

View full text Add to dashboard Cite

Congenital heart disease (CHD) affects a considerable number of children and adults worldwide. This implicates not only developmental disorders, high mortality, and reduced quality of life but also, high costs for the healthcare systems. CHD refers to a variety of heart and vascular malformations which could be very challenging to reconstruct the malformed region surgically, especially when the patient is an infant or a child. Advanced technology and research have offered a better mechanistic insight on the impact of CHD in the heart and vascular system of infants, children, and adults and identified potential therapeutic solutions. Many artificial materials and devices have been used for cardiovascular surgery. Surgeons and the medical industry created and evolved the ball valves to the carbon-based leaflet valves and introduced bioprosthesis as an alternative. However, with research further progressing, contracting tissue have been developed in the lab and tissue engineering (TE) could represent a revolutionary answer for CHD surgery. Development of engineered tissue for cardiac and aortic reconstruction for developing bodies of infants and children can be very challenging. Nevertheless, the use of acellular scaffolds, allograft, xenografts, and autografts are already very common. Seeding of cells on surface and within scaffold is a key challenging factor for use of the above. The use of different types of stem cells has been investigated and proven to be suitable for tissue engineering. They are the most promising source of cells for heart reconstruction in a developing body, even for adults. Some stem cell types are more effective than others, with some disadvantages which may be eliminated in the future.

show abstract

Section: Cardiac Progenitor Cellsmentioning

confidence: 99%

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Peer Review #1 of "Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease (v0.2)"

Ellison-Hughes¹

2018

View full text Add to dashboard Cite

show abstract

“…Lu et al have further examined the effects of pharmacological agents on repopulated heart and observed remarkable responses ( Zimmermann, Melnychenko & Eschenhagen, 2004 ). This model is explored as an option to personalized medicine concerning drug testing/discovery ( Zimmermann, Melnychenko & Eschenhagen, 2004 ; Bosman et al, 2015 ). Specifically, for CHD which presents such a variety of profiles, individual patient-specific human models’ development could help to understand how each patient would respond to existing pharmaceutical treatments.…”

Section: Congenital Heart Disease: Types Malformations Presentationmentioning

confidence: 99%

“…These c-kit+ CD45-(deletion of which also renders the cells CD31-, CD34-) CPCs were also shown to express to some degree Sca-1, Abcg2, CD105, CD166, PDGFR- α , Flk-1, ROR2, CD13, and CD90 ( Vicinanza et al, 2017 ). The number of CPCs have however been shown to be significantly higher in neonates but dramatically decreases after the age of 2 ( Chaikof, 2007 ; Bosman et al, 2011 ). Thus, these CPCs in combination with a suitable scaffold, could be the answer to treat a number of CHD, as CPCs could be collected during palliative surgery or via endomyocardial biopsy ( Saxena, 2010 ; Torok, 2015 ).…”

Section: Congenital Heart Disease: Types Malformations Presentationmentioning

confidence: 99%

Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease

Mantakaki¹,

Fakoya

Sharifpanah

2018

PeerJ

View full text Add to dashboard Cite

Congenital heart disease (CHD) affects a considerable number of children and adults worldwide. This implicates not only developmental disorders, high mortality, and reduced quality of life but also, high costs for the healthcare systems. CHD refers to a variety of heart and vascular malformations which could be very challenging to reconstruct the malformed region surgically, especially when the patient is an infant or a child. Advanced technology and research have offered a better mechanistic insight on the impact of CHD in the heart and vascular system of infants, children, and adults and identified potential therapeutic solutions. Many artificial materials and devices have been used for cardiovascular surgery. Surgeons and the medical industry created and evolved the ball valves to the carbon-based leaflet valves and introduced bioprosthesis as an alternative. However, with research further progressing, contracting tissue has been developed in laboratories and tissue engineering (TE) could represent a revolutionary answer for CHD surgery. Development of engineered tissue for cardiac and aortic reconstruction for developing bodies of infants and children can be very challenging. Nevertheless, using acellular scaffolds, allograft, xenografts, and autografts is already very common. Seeding of cells on surface and within scaffold is a key challenging factor for use of the above. The use of different types of stem cells has been investigated and proven to be suitable for tissue engineering. They are the most promising source of cells for heart reconstruction in a developing body, even for adults. Some stem cell types are more effective than others, with some disadvantages which may be eliminated in the future.

show abstract

“…Some reports concerning the use of stem cells to attempt to repair the myocardium have appeared [25,40,41]. This work is in its infancy, and often has revolved around the use of mesenchymal stem cells.…”

Section: Functional Cells Healing Cells and Maintenance Cellsmentioning

confidence: 99%

Cardiovascular Disease and Adult Healing Cells: From Bench Top to Bedside

Young¹,

Limnios²,

Lochner³

et al. 2017

Stem Cells Regen Med

View full text Add to dashboard Cite

Cardiovascular disease, especially ischemic heart disease resulting from coronary artery disease (CAD), is one of the major causes of death and disability in the United States. Even though the dead myocardial cells can be replaced by scar tissue in the healing process, the resulting myocardium cannot function as well as the preinfarcted myocardium, because scar tissues cannot contract. This "normal" healing process results in decreased cardiac output, which can lead to heart failure. Moreover, the scar tissue has abnormal electrical properties, which can lead to sometimes fatal arrhythmias. Previous studies demonstrated that when Lac-Z-labeled healing cells were infused into two animal models of myocardial infarction, that these cells were found to be located within the myocardium, the cardiac skeleton, and the vasculature undergoing repair. These results suggested that healing cells have the potential to repair damaged hearts. The current series of studies were undertaken to determine whether healing cells customarily reside in normal non-injured hearts of small and large animals, and whether autologous healing cells could be infused safely into a post-myocardial infarction patient. Adult rats were euthanized following the guidelines of Mercer University's IACUC. Adult pigs were euthanized following the guidelines of Fort Valley State University's IACUC. The human study was performed under the guidance of the Medical Center of Central Georgia's IRB. Animal hearts were harvested, fixed, cryosectioned, and stained with three antibodies: carcinoembryonic antigen-cell adhesion molecule-1 (CEA-CAM-1) for totipotent stem cells, stage-specific embryonic antigen-4 (SSEA-4) for pluripotent stem cells, and smooth muscle alpha-actin (IA4) for smooth muscle in the wall of the accompanying vasculature, thus serving as the positive procedural control. Cells positive for both CEA-CAM-1 and SSEA-4 were found to be located in adult rat and porcine hearts. Infusion of autologous healing cells into a post-myocardial infarcted patient resulted in an increase in their cardiac output after two successive healing cell infusions. Current IRB-approved studies are underway to assess the safety and efficacy of infused healing cells into individuals with cardiovascular disease.

show abstract

Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease

Cited by 8 publications

References 77 publications

Peer Review #1 of "Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease (v0.2)"

Peer Review #1 of "Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease (v0.2)"

Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease

Cardiovascular Disease and Adult Healing Cells: From Bench Top to Bedside

Contact Info

Product

Resources

About